METHOD OF PREVENTION AND TREATMENT OF AGING, AGE-RELATED DISORDERS AND/OR AGE-RELATED MANIFESTATIONS INCLUDING ATHEROSCLEROSIS, PERIPHERAL VASCULAR DISEASE, CORONARY ARTERY DISEASE, OSTEOPOROSIS, ARTHRITIS, TYPE 2 DIABETES, DEMENTIA, ALZHEIMERS DISEASE AND CANCER

• US 20060275294A1
• Filed: 04/10/2006
• Published: 12/07/2006
• Est. Priority Date: 08/22/2002
• Status: Abandoned Application

• Current Assignee: Osemwota Sota Omoigui
• Original Assignee: Osemwota Sota Omoigui
• Inventors: Omoigui, Osemwota Sota
• Application Number:
  US11/279,239
• Publication Number:
  US 20060275294A1
• Time in Patent Office: Days
• US Class Current: 424/145.100
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/22 of acyclic acids, e.g. pravastatin
• CPC Class Codes: A61K 31/353 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• CPC Class Codes: A61K 31/366 having six-membered rings, e.g. delta-lactones
• CPC Class Codes: A61K 31/401 Proline; Derivatives thereof, e.g. captopril
• CPC Class Codes: A61K 31/663 Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
• CPC Class Codes: A61K 31/675 having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• CPC Class Codes: A61K 31/7048 having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin , digitoxin or digoxin
• CPC Class Codes: A61K 36/062 Ascomycota
• CPC Class Codes: A61K 36/899 Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

This invention relates to a method for prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, type 2 diabetes, dementia and some forms of arthritis and cancer in a subject comprising administering to said subject, separately, sequentially or simultaneously a therapeutically effective dosage of each component or combination of statins, bisphosphonates, cholesterol lowering agents or techniques, interleukin-6 inhibitor/antibody, interleukin-6 receptor inhibitor/antibody, interleukin-6 antisense oligonucleotide (ASON), gp130 protein inhibitor/antibody, tyrosine kinases inhibitors/antibodies, serine/threonine kinases inhibitors/antibodies, mitogen-activated protein (MAP) kinase inhibitors/antibodies, phosphatidylinositol 3-kinase (PI3K) inhibitors/antibodies, Nuclear factor κB (NF-κB) inhibitors/antibodies, IκB kinase (IKK) inhibitors/antibodies, activator protein-1 (AP-1) inhibitors/antibodies, STAT transcription factors inhibitors/antibodies, altered IL-6, partial peptides of IL-6 or IL-6 receptor, or SOCS (suppressors of cytokine signaling) protein, or a functional fragment thereof, administered separately, in sequence or simultaneously. Inhibition of the signal transduction pathway for Interleukin 6 mediated inflammation is key to the prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, aging, age-related disorders and/or age-related manifestations including osteoporosis, type 2 diabetes, dementia and some forms of arthritis and tumors. Inhibition of Interleukin 6 mediated inflammation may be achieved indirectly through regulation of endogenous cholesterol synthesis and isoprenoid depletion or by direct inhibition of the signal transduction pathway utilizing interleukin-6 inhibitor/antibody, interleukin-6 receptor inhibitor/antibody, interleukin-6 antisense oligonucleotide (ASON), gp130 protein inhibitor/antibody, tyrosine kinases inhibitors/antibodies, serine/threonine kinases inhibitors/antibodies, mitogen-activated protein (MAP) kinase inhibitors/antibodies, phosphatidylinositol 3-kinase (PI3K) inhibitors/antibodies, Nuclear factor κB (NF-κB) inhibitors/antibodies, IκB kinase (IKK) inhibitors/antibodies, activator protein-1 (AP-1) inhibitors/antibodies, STAT transcription factors inhibitors/antibodies, altered IL-6, partial peptides of IL-6 or IL-6 receptor, or SOCS (suppressors of cytokine signaling) protein, or a functional fragment thereof. Said method for prevention and treatment of said disorders is based on inhibition of Interleukin-6 inflammation through regulation of cholesterol metabolism, isoprenoid depletion and/or inhibition of the signal transduction pathway

Claims

1-96. -96. (canceled)

97. A method for treating an age-related disorder in a human or animal subject comprising administering to said subject an effective amount of an anti-Interleukin-6 (IL-6) anti-inflammatory agent that inhibits IL-6-mediated inflammation in said subject.

98. The method of claim 97, wherein said anti-IL-6 anti-inflammatory agent inhibits IL-6-mediated inflammation in said subject by modulating endogenous cholesterol synthesis in the subject.

99. The method of claim 97, wherein said anti-IL-6 anti-inflammatory agent inhibits IL-6-mediated inflammation in said subject by modulating endogenous isoprenoid depletion in the subject.

100. The method of claim 99, wherein said anti-IL-6 anti-inflammatory agent inhibits IL-6-mediated inflammation in said subject by inhibiting cholesterol synthesis in the subject.

101. The method of claim 100, wherein said anti-IL-6 anti-inflammatory agent that inhibits cholesterol synthesis in the subject is selected from statins, and bisphosphonates.

102. The method of claim 100, wherein said anti-IL-6 anti-inflammatory agent that inhibits cholesterol synthesis in the subject is a statin or statin-containing composition selected from the group consisting of lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, rivastatin, red yeast rice, red yeast grain, red yeast powder, and fermentation products of a filamentous fungi.

103. The method of claim 100, wherein said anti-IL-6 anti-inflammatory agent that inhibits cholesterol synthesis in the subject is a bisphosphonate selected from the group consisting of pamidronate, etidronate, clodronate, amdalendronate, and phosphonic acid derivatives and esters thereof.

104. The method of claim 98, wherein said anti-IL-6 anti-inflammatory agent that inhibits IL-6-mediated inflammation is a cholesterol lowering agent.

105. The method of claim 104, wherein said cholesterol lowering agent is selected from the group consisting of (i) cholesterol sequestrants, (ii) nicotinyl alcohol, nicotinic acid, and salts thereof, (iii) PPAR alpha agonists, (iv) inhibitors of cholesterol absorption, (v) phytosterols and phytosterol-containing food products, and (vi) acyl CoA:

cholesterol acyltransferase inhibitors.

106. The method of claim 97, wherein said anti-IL-6 anti-inflammatory agent inhibits IL-6-mediated inflammation in said subject by inhibiting IL-6 expression, activity, and/or signal transduction in the subject.

107. The method of claim 106, wherein said anti-IL-6 anti-inflammatory agent is an anti-IL6 antibody or inhibitor that binds, neutralizes, and/or inhibits a signal transduction activity of IL-6, or an anti-IL6 receptor antibody or inhibitor that binds, neutralizes, and/or inhibits a signal transduction activity of an IL-6 receptor.

108. The method of claim 106, wherein said anti-IL-6 anti-inflammatory agent is an antisense oligonucleotide (ASON) that inhibits IL-6 expression in said subject.

109. The method of claim 106, wherein said anti-IL-6 anti-inflammatory agent is an antibody or inhibitor directed against one or more endogenous targets involved in IL-6 signal transduction and/or metabolism selected from gp130 protein, tyrosine kinases, serine/threonine kinases, mitogen-activated protein (MAP) kinases, phosphatidylinositol 3-kinase (PI3K), Nuclear factor κ

B (NF-κ

B), Iκ

B kinase (IKK), activator protein-1 (AP-1), and STAT transcription factors.

110. The method of claim 109, wherein said anti-IL-6 anti-inflammatory agent is selected from suppressors of cytokine signaling (SOCS) proteins, activators and ligands of PPAR gamma and PPAR beta/delta, and functional fragments thereof.

111. The method of claim 109, wherein said anti-IL-6 anti-inflammatory agent is selected from the group consisting of inactive and active forms of vitamin D, 1-alpha, 25-dihydroxyvitamin D3 (1-alpha, 25 (OH)2D3) and its analogs;

synthetic or plant derived polyphenolic compounds including phenolic acids, flavonoids, stilbenes, lignans, and anthocyanidins;

flavanols;

flavones;

flavonols, flavanones, isoflavones and their naturally occurring glycosides;

proanthocyanidins and their gallic acid esters;

soy protein material and their naturally occurring glycosides;

soy-based food products and soybean-derived protein ingredients;

Cocoa polyphenols and derivatives thereof;

polyphenols found in nuts, nut skin extracts, tea and derivatives thereof;

polyphenols of vegetables and fruits;

polyphenols derived from fruits, vegetables, cereals, dry legumes, chocolate, and beverages including grape juice tea, coffee, or wine; and

Omega 3 fatty acids.

112. The method of claim 106, wherein said anti-IL-6 anti-inflammatory agent comprises an altered IL-6, a partial peptide of IL-6, or an IL-6 receptor protein or peptide.

113. The method of claim 112, wherein said IL-6 or IL-6 receptor protein or peptide is artificially modified by a recombinant or chemical alteration.

114. The method of claim 97, wherein said age-related disorder is atherosclerosis.

115. The method of claim 97, wherein said age-related disorder is peripheral vascular disease.

116. The method of claim 97, wherein said age-related disorder is coronary artery disease.

117. The method of claim 97, wherein said age-related disorder is arrhythmia.

118. The method of claim 97, wherein said age-related disorder is hypertension

119. The method of claim 97, wherein said age-related disorder is osteoporosis

120. The method of claim 97, wherein said age-related disorder is arthritis

121. The method of claim 97, wherein said age-related disorder is type 1 diabetes, type 2 diabetes, inadequate glucose tolerance or insulin resistance.

122. The method of claim 97, wherein said age-related disorder is obesity.

123. The method of claim 97, wherein said age-related disorder is dementia

124. The method of claim 97, wherein said age-related disorder is Alzheimer'"'"'s disease Huntington'"'"'s disease, or Parkinson'"'"'s disease.

125. The method of claim 97, wherein said age-related disorder is skin wrinkles, sunburn, or skin damage.

126. The method of claim 97, wherein said age-related disorder is age-related macular degeneration (AMD).

127. The method of claim 97, wherein said age-related disorder is periodontal disease.

128. The method of claim 97, wherein said age-related disorder is a chronic low grade infection.

129. The method of claim 97, wherein said age-related disorder is a primary or secondary cancer or tumor selected from the group consisting of adrenal cancer, astrocytoma, basal or squamous cell carcinoma, brain cancer, bladder cancer, breast cancer, colorectal cancer, chrondrosarcoma, cervical cancer, choriocarcinoma, esophageal cancer, endometrial carcinoma, erythroleukemia, Ewing'"'"'s sarcoma, gastrointestinal cancer, gliobastoma, glioma, head and neck cancer, hepatocellular carcinoma, hepatoma, leiomyoma, leukemia, melanoma, multiple myeloma, neural cancer, lung cancer, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, rhabdomyosarcoma, small cell lung cancer, testicular cancer, and thyroid cancer.

130. The method of claim 97, wherein said anti-Interleukin-6 (IL-6)-inflammatory agent is administered to said subject subcutaneously, intramuscularly, intravenously, orally, rectally, sublingually, transmucosally, inhalationally, or transdermally.

131. The method of claim 97, wherein said anti-IL-6 anti-inflammatory agent is administered to said subject by gene therapy or gene modulation.

132. The method of claim 131, wherein said anti-IL-6 anti-inflammatory agent is an altered IL-6 gene modified by a base change of guanine to cytosine at position 174 in a 5′

flanking region of the interleukin-6 gene.

133. The method of claim 131, wherein said anti-IL-6 anti-inflammatory agent is an altered IL-6 gene administered to a cell as naked DNA.

134. The method of claim 131, wherein said anti-IL-6 anti-inflammatory agent is an altered IL-6 gene administered to a cell in a vector.

135. The method of claim 134, wherein said vector comprises a promoter or regulator to control expression of the interleukin-6 gene.

136. The method of claim 134, wherein said vector comprises targeting means to target the vector to a particular tissue or cell type.

137. The method of claim 134, wherein said vector comprises a viral vector.

138. The method of claim 134, wherein said vector is derived from a DNA virus, an RNA virus, or a retrovirus.

139. The method of claim 134, wherein said vector comprises an adenovirus vector.

140. The method of claim 131, wherein gene modulation of an interleukin-6 gene is achieved by introducing to said subject an antisense gene or gene fragment, or by introducing to said subject a vector that produce a ribozyme that cleaves a specific mRNA.

141. The method of claim 131, wherein said gene modulation is achieved by introduction of an exogenous normal genetic sequence that codes for a protein that modulates gene expression or affects processing, assembly, or secretion of a gene product.